An annual report from the American Cancer Society shows that, for the first time, over 70% of Americans diagnosed with cancer ...

Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why. A new study published in JAMA Oncology from ...

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

An 82-year-old former TV presenter who still plays the drums in the West Midlands after successful cancer treatment is ...

Pancreatic cancer has long resisted immunotherapy, but scientists have uncovered a subtle way these tumors evade immune attack. By exploiting a sugar-based “don’t harm me” signal normally used by ...

Vonjo shows promise in improving blood counts for myelofibrosis patients, enhancing quality of life by reducing anemia-related symptoms. Antibody-drug conjugates are increasingly used in metastatic ...

Explore advancements in prostate cancer treatment, focusing on the role of rectal spacers in enhancing radiation therapy safety and effectiveness. In this segment, the panel outlines the complementary ...

Could guts save your butt? A new study reports that bacteria found in the intestines of Japanese tree frogs show remarkable promise in treating colorectal cancer. A research team from the Japan ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...